Clinical trials: irinotecan hydrochloride
Bile Duct Cancer
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours
Bile duct tumours are rare. They are the 6th most common type of digestive cancer. Their therapeutic management is complex and must be multidisciplinary in nature.
- Trial name
- AMEBICA (NCT02591030)
- Testing
- GEMCIS, mFolfirinox
- Where
- 42 sites in France
- Volunteers
- 191 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Microsatellite Stable Metastatic Colorectal Cancer
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
TORCH-M is a prospective, single-arm, two-cohort, investigator-initiated phase II trial to investigate the efficacy and safety of standard systemic therapy in combination with high/low-dose radiotherapy plus toripalimab in…
- Trial name
- NCT06525428
- Testing
- standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Fudan University
Rhabdomyosarcoma
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
- Trial name
- FaR-RMS (NCT04625907)
- Testing
- Irinotecan, Actinomycin D, Doxorubicin
- Where
- 128 sites in Australia, Austria and 18 more
- Volunteers
- 1,672 people
- Sponsor
- University of Birmingham
Stomach Neoplasms
Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding
Stomach cancer is the most common cancer, and is still leading cause of death in Korea. Peritoneal seeding is the most common metastases of gastric cancer, and is the most frequent cause of death from this disease.
- Trial name
- NCT00539877
- Testing
- irinotecan
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Samsung Medical Center
Small Cell Lung Cancer Extensive Stage
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment…
- Trial name
- NCT06739928
- Testing
- Irinotecan liposome (II) combined with adebrelimab and carboplatin, etoposide combined with adebrelimab and carboplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005036
- Testing
- irinotecan hydrochloride, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
A Phase II study of temsirolimus in combination with standard chemotherapy (irinotecan; cyclophosphamide, doxorubicin and etoposide (CAE); cisplatin and etoposide (HiPE) and topotecan (TPT) followed by and additional six courses…
- Trial name
- NCT00808899
- Testing
- Temsirolimus, Irinotecan, Surgical Resection of Primary Tumor
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Unspecified Adult Solid Tumor, Protocol Specific
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in treating patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT00119236
- Testing
- tanespimycin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
- Trial name
- NCT07376499
- Testing
- Liposome Irinotecan, Platinum, Anlotinib
- Volunteers
- 31 people
- Sponsor
- China Medical University, China
Rectal Cancer
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer
Irinotecan is one of effective drugs for colorectal cancer. In neoadjuvant chemoradiotherapy (CRT), Irinotecan is prescribed in a low dose of 50mg/m2/week because of toxicity.
- Trial name
- NCT01474187
- Testing
- Irinotecan, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Esophageal Cancer, Gastric Cancer
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00397904
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.
- Trial name
- NCT04569916
- Testing
- radiotherapy, irinotecan liposome, apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Colorectal Cancer, Liver Metastases
Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis
Trans arterial chemoembolization using Irinotecan Drug-eluting Beads before liver surgery for patients with primarily unresectable colorectal liver metastasis
- Trial name
- NCT04912258
- Testing
- Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional chemotherapy with the FOLFOX regimen as…
- Trial name
- NCT02128425
- Testing
- FOLFOXIRI, FOLFOX
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Small Bowel Adenocarcinoma
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
The study regimen will be administered on an outpatient basis and all medications are administered intravenously (IV). Subjects will receive treatment on Day 1 and Day 15 of each 28-day cycle consisting of the following…
- Trial name
- NCT06835387
- Testing
- Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tiago Biachi de Castria
Gastric Cancer
FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)
FOLFOX* followed by FOLFIRI** or reverse sequence treatment regimen have been used as a standard treatment modality in metastatic colorectal cancer.Oxaliplatin and Irinotecan were used for advanced gastric cancer also.
- Trial name
- NCT01138904
- Testing
- irinotecan, oxaliplatin, oxaliplatin, irinotecan
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Dong-A University Hospital
Colorectal Carcinoma
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and…
- Trial name
- NCT00051987
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Where
- 22 sites in United States
- Volunteers
- 175 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Pancreatic Cancer
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
- Trial name
- NCT03336216
- Testing
- Cabiralizumab, Nab-paclitaxel, Onivyde
- Where
- 41 sites in United States, Canada and 9 more
- Volunteers
- 205 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Since its introduction, 5-fluorouracil (5-FU) has been the cornerstone of treatment for metastatic colorectal cancer (mCRC). Meanwhile the oral 5FU pro-drug Capecitabine (Xeloda®) proved equivalence to 5-FU and is a well…
- Trial name
- PASSION (NCT02119026)
- Testing
- Capecitabine, Bevacizumab, Oxaliplatin
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Prof. Dr. Werner Scheithauer
Colorectal Cancer Metastatic
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal…
- Trial name
- NCT06973343
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Provincial Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.